Key result
Rosuvastatin daily resulted in greater reductions in LDL-C and inflammatory biomarkers compared to atorvastatin daily.
Why the study?
Statins reduce the risk of atherosclerotic cardiovascular complications in T2D patients, but the comparative efficacy of rosuvastatin versus atorvastatin on LV function and inflammatory markers in dyslipidemic T2D patients required examination.
Does rosuvastatin improve inflammatory biomarkers and LV function compared to atorvastatin in type 2 diabetic patients with dyslipidemia?
RCT (n=160)
Does rosuvastatin improve inflammatory biomarkers and LV function compared to atorvastatin in type 2 diabetic patients with dyslipidemia?
Rosuvastatin 10 mg daily provides greater improvements in lipid profiles and inflammatory biomarkers than atorvastatin 40 mg daily in patients with type 2 diabetes and dyslipidemia, though both similarly preserve LV function.
Answers are grounded in this paper and cite their sources.
Rosuvastatin may be preferred over atorvastatin in T2D with dyslipidemia for LV and inflammatory benefits; extends RCT evidence of differential statin pleiotropy.
BACKGROUND: Statins are potential drugs for decreasing risk of atherosclerotic cardiovascular complications in type 2 diabetic (T2D) patients. PURPOSE: To examine the efficacy of both rosuvastatin (ROSUVA) and atorvastatin (ATORVA) on LV function and markers of inflammation in T2D patients with dyslipidemia. METHODS: One hundred-sixty T2D patients were assigned to receive either atorvastatin (ATORVA group, n = 80, 40 mg) or rosuvastatin (ROSUVA group, n = 80, 10 mg), daily for 6 months. Blood was collected for biochemical analysis. The prevalence of left ventricular abnormalities was determined by echocardiography and two-dimensional Speckle-Strain to assess Global Longitudinal Strain (GLS). RESULTS: ROSUVA vs. ATORVA resulted in significant (p < 0.001) reduction in HbA1c % (9.13 vs 2.35%), LDL-C (22.23% vs. 14.75%), triglycerides (13.56 % vs. 8.21 %), total cholesterol (16.10 % vs. 10.81 %), atherogenic index (18.08. % vs. 10.97%), hs-CRP (23.51 % vs.18.96%), sortilin (33.33 % % vs. 15.08 %), and leptin (31.81 % vs. 23.17 %) but increased adiponectin (97.99 % vs.76.47.1 %) and HDL-C (76.47 % vs. 0.21 %) compared with baseline, respectively. Negative correlations between adiponectin and each of hs-CRP, HbA1c%, total cholesterol, LDL-C, atherogenic index and leptin were found. Also, left ventricular functions were correlated with adiponectin, lipids, HbA1c% and hs-CRP. The areas under receiver operating characteristic curve (AUC) showed that hs-CRP, leptin, sortlin, leptin, and adiponectin were good predictors for cardiovascular events. CONCLUSION: ROSUVA is more efficacious in improving lipid profile, atherogenic index and modulation of inflammatory biomarkers in dyslipidemic T2D patients compared with ATROVA. However, both statins are equivalent as cardioprotective agents in dyslipidemic T2D patients.
No takes yet. Share an insight, caveat, or question.
Werida et al. (2021) conducted an RCT in Type 2 diabetes with dyslipidemia (n=160). Rosuvastatin vs. Atorvastatin 40 mg daily was evaluated on LDL-C reduction (p=<0.001). Rosuvastatin daily resulted in greater reductions in LDL-C and inflammatory biomarkers compared to atorvastatin daily.
Synapse has enriched 10 related papers. Consider them for comparative context: